Citation: | Jianjun Wu, Yahan Fan, Zhanshan Cha, Shijie Mu, Zhongjun Li, Jiwu Gong, Qiushi Wang, Haiyan Wang, Jiubo Liu, Fenghua Liu, MingChia Yang, Juan Zhang, Xuelian Zhou, Jue Xie, Mei Qin, Zebo Yu, Xianjun Ma, Yanli Bai, Xiaoyu Zhou, Yan Bai, Yongjun Wang, Shouyong Hun, Pu Xu, Jiajin Lin, Chunxia Liu, Jing Chen, Hui Wang, Xiaoning Wang, Liying Xu, Quanli Wang, Shuming Zhao. Expert consensus on standard operating procedures for autologous ozonized blood transfusion[J]. Blood&Genomics, 2022, 6(2): 73-80. doi: 10.46701/BG.2022022022022 |
[1] |
The International Scientific Committee of Ozone Therapy. Madrid declaration on ozone therapy: version 3[EB/OL]. [2020-05-14]. http://www.isco3.org/.
|
[2] |
Bocci V. Oxygen-ozone therapy[M]. Beijing: Peking University Medical Press, 2006.
|
[3] |
Chinese Society of Anesthesiology Committee for Pain Medicine, Chinese Association of Anesthesiology, Chinese Medical Association of Minorities Committee for Ozone Medicine. Expert consensus on ozonated autohemotherapy[J]. Transl Med J, 2018, 7(6): 326−328, 345. doi: 10.3969/j.issn.2095-3097.2018.06.002
|
[4] |
Ma YL, Guo L, Dai ZQ, et al. Clinical research progress of medical ozonated autohemotherapy[J]. Electron J Clin lit, 2019, 6(83): 197. doi: 10.16281/j.cnki.jocml.2019.83.147
|
[5] |
Pivotto AP, Banhuk FW, Staffen IV, et al. Clinical uses and molecular aspects of ozone therapy: a review[J]. OnLine J Biol Sci, 2020, 20(1): 37−49. doi: 10.3844/ojbsci.2020.37.49
|
[6] |
Cattel F, Giordano S, Bertiond C, et al. Ozone therapy in COVID-19: a narrative review[J]. Virus Res, 2021, 291: 198207. doi: 10.1016/j.virusres.2020.198207
|
[7] |
Hernández A, Viñals M, Pablos A, et al. Ozone therapy for patients with COVID-19 pneumonia: preliminary report of a prospective case-control study[J]. Int Immunopharmacol, 2021, 90: 107261. doi: 10.1016/j.intimp.2020.107261
|
[8] |
Tascini C, Sermann G, Pagotto A, et al. Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience[J]. Intern Emerg Med, 2021, 16(3): 669−675. doi: 10.1007/s11739-020-02542-6
|
[9] |
National Health Commission of the People's Republic of China. Technical specifications for clinical blood transfusion[S/OL]. [2001-11-08]. http://www.nhc.gov.cn/wjw/gfxwj/200111/2c93606209ec4a25ad9241787f9f7404.shtml.
|
[10] |
National Health and Family Planning Commission of the People's Republic of China. Blood station management[S]. [2018-08-30]. http://www.nhc.gov.cn/fzs/s3576/201808/17c156cdbff24e479eec30717f986ec8.shtml.
|
[11] |
National Health and Family Planning Commission of the People's Republic of China. Quality management standard for blood station[S]. [2006-07-10]. http://www.nhc.gov.cn/yzygj/s3589/200804/6d133e61f45f49c5b7737a8d8e6458fb.shtml.
|
[12] |
Peng GF, Yu KQ, Li M, et al. Effect comparison of different concentrations of medical ozonated autohemotherapy in the treatment of acute gouty arthritis[J]. Shandong Med J, 2021, 61(5): 79−81. doi: 10.3969/j.issn.1002-266X.2021.05.022
|
[13] |
Feng LF, Chen N, Li XX, et al. Effectiveness and safety of trioxy autotransfusion therapy for gout: a systematic review and meta analysis[J]. Chin J Drug Eval, 2021, 38(5): 425−430.
|
[14] |
Tan YC, Guo JP, Wang CF, et al. Clinical effect of immune ozonated autohemotherapy in the treatment of hyperlipidemia[J]. Women's Health Res, 2019, 0(12): 57−58.
|